The Food and Drug Administration last week authorized administering the monoclonal antibodies bamlanivimab and etesevimab together to prevent COVID-19 in certain children and adults exposed to SARS-CoV-2 who are not fully vaccinated against COVID-19 and at high-risk for progressing to severe disease. 

The combination therapy is currently authorized for use only in states and territories having 5% or fewer variants resistant to bamlanivimab and etesevimab administered together.

FDA last month authorized using the monoclonal antibody therapy REGEN-COV to prevent COVID-19 in such patients. 
 

Related News Articles

Headline
Abbott Molecular Inc. yesterday issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and…
Headline
The Centers for Disease Control and Prevention yesterday released an operational planning guide for pediatric COVID-19 vaccination and preliminary information…
Headline
Available data support the safety and effectiveness of the Johnson & Johnson COVID-19 vaccine for emergency use authorization as a booster dose in…
Headline
A Food and Drug Administration advisory panel today voted unanimously to recommend an extra Moderna booster dose for certain individuals. The Vaccines and…
Headline
The AHA today launched a new video series, Vaccines Work, highlighting all the successful vaccines that have helped fight severe disease and illness, such as…
Headline
A new study released today by the National Academies of Sciences, Engineering and Medicine offers advice for communicating with parents about their children’s…